AR039166A1 - Composiciones de venlafaxina base - Google Patents

Composiciones de venlafaxina base

Info

Publication number
AR039166A1
AR039166A1 ARP030101074A ARP030101074A AR039166A1 AR 039166 A1 AR039166 A1 AR 039166A1 AR P030101074 A ARP030101074 A AR P030101074A AR P030101074 A ARP030101074 A AR P030101074A AR 039166 A1 AR039166 A1 AR 039166A1
Authority
AR
Argentina
Prior art keywords
venlafaxine
base
compositions
liquid phase
pharmaceutical composition
Prior art date
Application number
ARP030101074A
Other languages
English (en)
Inventor
Escoi Joan Cucala
Luengo Montserrat Gallego
Marinus Jacobus Maria Oosterbaan
Frantisek Picha
Original Assignee
Synthon Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon Bv filed Critical Synthon Bv
Publication of AR039166A1 publication Critical patent/AR039166A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composición farmacéutica que comprende una venlafaxina base sólida y un excipiente farmacéuticamente aceptable, a un procedimiento para preparar una composición de venlafaxina, que comprende dispersar venlafaxina base en un portador de fase líquida; y solidificar dicha fase líquida para formar una dispersión sólida de venlafaxina, y al uso de una composición farmacéutica como un medicamento.
ARP030101074A 2002-03-28 2003-03-27 Composiciones de venlafaxina base AR039166A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36773602P 2002-03-28 2002-03-28

Publications (1)

Publication Number Publication Date
AR039166A1 true AR039166A1 (es) 2005-02-09

Family

ID=28675392

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP030101073A AR039165A1 (es) 2002-03-28 2003-03-27 Venlafaxina base
ARP030101074A AR039166A1 (es) 2002-03-28 2003-03-27 Composiciones de venlafaxina base

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP030101073A AR039165A1 (es) 2002-03-28 2003-03-27 Venlafaxina base

Country Status (5)

Country Link
US (2) US20030190352A1 (es)
EP (1) EP1487429A2 (es)
AR (2) AR039165A1 (es)
AU (2) AU2003226748A1 (es)
WO (2) WO2003082806A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060246132A1 (en) * 2003-02-07 2006-11-02 Fjalar Johannsson Sustained release formulations of venlafaxine
US20050048118A1 (en) * 2003-07-25 2005-03-03 Joan Cucala Escoi Modified release venlafaxine hydrochloride tablets
EP1523979A1 (en) * 2003-10-13 2005-04-20 Wyeth Extended release pharmaceutical dosage form
US20050142203A1 (en) * 2003-12-30 2005-06-30 Grant Heinicke Oral dosage formulations of active pharmaceutical ingredients and methods of preparing the same
DE602004006443T2 (de) * 2004-02-04 2008-01-10 Alembic Ltd., Vadodara Beschichtete minitabletten von venlafaxinhydrochlorid mit verlängerter freisetzung
JP2007520553A (ja) * 2004-02-06 2007-07-26 ワイス 多微粒子ｏ−デスメチルベンラファキシン塩およびその使用
ATE554752T1 (de) 2004-02-06 2012-05-15 Pharmatel R & D Pty Ltd As Trustee For The Pharmatel R & D Trust Verwendung von aminosalicylaten beim reizdarmsyndrom mit durchfall als vorherrschendem symptom
AU2004319799A1 (en) * 2004-05-21 2005-12-01 Lupin Ltd. Novel extended release composition of Venlafaxine hydrochloride containing polyvinyl acetate
JP5009152B2 (ja) * 2004-05-28 2012-08-22 サリックス ファーマシューティカルズ， インコーポレイテッド 放射線誘発性腸炎の予防、処置、および回復
CN1955159B (zh) 2005-06-17 2010-11-24 山东绿叶制药有限公司 用于阻断5-羟色胺以及去甲基肾上腺素再摄取的化合物,其制备方法及其用途
WO2007011619A2 (en) * 2005-07-15 2007-01-25 Wyeth Highly bioavailable oral delayed release dosage forms of o-desmethylvenlafaxine succinate
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
EP2529729A1 (en) * 2005-08-24 2012-12-05 Salix Pharmaceuticals, Inc. Balsalazide formulations and manufacture thereof
CN102212014B (zh) * 2010-04-09 2013-12-25 江苏豪森医药集团有限公司 O-去甲基-文拉法辛的谷氨酸盐的晶型、其制备方法及其在医药上的应用
US20130034604A1 (en) * 2010-05-14 2013-02-07 Alembic Pharmaceuticals Limited Extended release formulations of desvenlafaxine base
CA2860747C (en) 2010-10-01 2015-08-11 Shan Dong Luye Pharmaceutical Co., Ltd. Polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methylbenzoate hydrochloride, methods for preparing the same and use of the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4535186A (en) * 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
GB8902209D0 (en) * 1989-02-01 1989-03-22 Wyeth John And Brother Limited Preparation of cyclohexanol derivatives and novel thioamide intermediates
DE69429895T2 (de) * 1993-06-28 2002-08-29 American Home Products Corp., Madison Neue Behandlungsmethoden durch Verwendung von Phenethylderivaten
US6274171B1 (en) * 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
UA77145C2 (en) * 1997-11-05 2006-11-15 Wyeth Corp Extended release dosage formulation
US6197828B1 (en) * 1998-12-01 2001-03-06 Sepracor, Inc. Derivatives of (+)-venlafaxine and methods of preparing and using the same
US20020022662A1 (en) * 1999-06-15 2002-02-21 American Home Products Corporation Enantiomers of O-desmethyl venlafaxine
YU43702A (sh) * 1999-12-23 2004-11-25 Pfizer Products Inc. Farmaceutske kompozicije koje obezbeđuju povećanje koncentracije leka
US20020183553A1 (en) * 2000-10-19 2002-12-05 Ben-Zion Dolitzky Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
SK5762003A3 (en) * 2000-10-19 2003-11-04 Teva Pharma Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
BR0100334A (pt) * 2001-01-17 2002-09-24 Diffucap Chemobras Quimica E F Processo para a preparação de composições de liberação programada contendo venlafaxina e o produto resultante

Also Published As

Publication number Publication date
WO2003082806A1 (en) 2003-10-09
US20030190352A1 (en) 2003-10-09
AU2003226748A8 (en) 2003-10-13
AU2003226752A1 (en) 2003-10-13
WO2003082262A2 (en) 2003-10-09
WO2003082262A3 (en) 2004-07-29
AR039165A1 (es) 2005-02-09
US20030191347A1 (en) 2003-10-09
EP1487429A2 (en) 2004-12-22
AU2003226748A1 (en) 2003-10-13

Similar Documents

Publication Publication Date Title
AR039166A1 (es) Composiciones de venlafaxina base
CL2004001267A1 (es) Compuestos derivados de quinazolina, inhibidor de quinasa; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso para preparar un medicamento para tratar trastornos proliferativos celulares tales como ateroesclerosis,
UY31406A1 (es) "producto de dispersion solida que contiene un compuesto a base de n-aril urea".
RS51569B (en) COMPOSITIONS CONTAINING CRYSTAL TRANS - (+/-) - DELTA-9-TETRAHYDROCANABINOL
BRPI0409133A (pt) formulações farmacêuticas contendo metilnaltrexona
UY29701A1 (es) Formulaciones líquidas para la administración controlada de derivados de bencisoxazol
CL2009001766A1 (es) Composicion farmaceutica solida para administracion oral que comprende: un taxano sustancialmente amorfo definido, un portador hidrofilico definido y un tensoactivo definido; metodo para preparar la composicion; y su uso para tratar una enfermedad neoplasica.
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
WO2010041141A3 (en) Oil-based foamable carriers and formulations
MX2009004203A (es) Combinaciones de paracetamol/ibuprofeno y metodo para su uso.
TW200607798A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
AR007827A1 (es) 3-ureido-piridofuranos y -piridotiofenos, procedimiento para su preparacion, composicion que los comprende y uso de dichos compuestos para lapreparacion de medicamentos.
TW200633964A (en) Tetralin and indane derivatives and uses thereof
BR0211601A (pt) Polimorfo estável de flibanserina, processo técnico para a preparação do mesmo e o uso do mesmo para a preparação de medicamentos
UY29896A1 (es) Nuevos derivados de cromano, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
AR034813A1 (es) Composiciones farmaceuticas y uso de las mismas
MX2008001560A (es) Nuevos compuestos analogos de la camptotecina, un procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
NO20042158L (no) Substituert 4-fenyl-tetrahydroisokinoliner, fremgangsmate for fremstilling derav, anvendelse derav som medikamenter, i tillegg til medikamenter inneholdende samme
ATE499939T1 (de) Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend
AR027360A1 (es) Composicion farmaceutica
UY29892A1 (es) Nuevos derivados de cromano, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones
CL2009000980A1 (es) Uso de (s)-n-(2-(1,6,8-tetrahidro-2h-inden[5,4-b]furan-8-il)etil]propionamida en combinacion con una o más drogas seleccionadas de un grupo definido para preparar un medicamento útil para la prevencion o tratamiento de la depresión o desórdenes de ansiedad (divisional de la solicitud 749-2006).
PL1868631T3 (pl) Zastosowanie związków indukujących syntezę białek SIRT przy lub dla otrzymywania kompozycji kosmetycznej lub farmaceutycznej
AR048672A1 (es) Tabletas de desintegracion que comprenden licarbazepina
TW200505436A (en) Modified release pharmaceutical compositions and the processes for preparing them

Legal Events

Date Code Title Description
FB Suspension of granting procedure